Targeted therapies: Cetuximab, chemotherapy and KRAS status in mCRC

Nature Reviews Clinical Oncology

Volumn 6, Issue 7, 2009, Pages 379-380

  Gill, Sharlene ^a   Goldberg, Richard M ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ONCOPROTEIN; OXALIPLATIN; PANITUMUMAB; PROTEIN KRAS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLFOXIRI PROTOCOL; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; RAS PROTEIN;

ALLERGIC REACTION; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; METASTASIS POTENTIAL; NEUROPATHY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; SURVIVAL RATE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; METHODOLOGY; MUTATION; NOTE; PHASE 3 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70349576885     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.83     Document Type: Article

References (9)

1. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
2. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
3. Arnold, D. et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer; A phase Ib/II study of the AIO GI group. Ann. Oncol. 19, 1442-1449 (2008).
4. Tabernero, J. et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25 5225-5232 (2007).
5. Bokemeyer, C. et al. Fluorouracil, leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663-671 (2008).
6. Jimeno, A. et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection. J. Clin. Oncol. 27, 1130-1136 (2009).
7. Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N. Engl. J. Med. 360, 1408-17 (2009).
8. Tol, J. et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer, N. Engl. J. Med. 360, 563-572 (2009).
9. Hecht, J. R. et al. A Randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672-680 (2009).